Björn-Ole Juhnke
  • Assistant physician
  • Medical Specialist in Pediatrics and Youth Medicine
Working area

Location

O47 , Ground Floor
Languages
German (Mother tongue)
English

Publications

2023

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, Ecker J, von Hoff K, Juhnke B, Goschzik T, Pietsch T, Bockmayr M, Kool M, von Deimling A, Witt O, Schüller U, Benesch M, Gerber N, Sahm F, Jones D, Korshunov A, Pfister S, Rutkowski S, Milde T
ACTA NEUROPATHOL. 2023;145(1):97-112.

Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy
Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, Milde T, Pietsch T, Goschzik T, Bison B, Juhnke B, Struve N, Sturm D, Sahm F, Bockmayr M, Friedrich C, von Bueren A, Gerber N, Benesch M, Jones D, Kool M, Wefers A, Schüller U, Pfister S, Rutkowski S, Mynarek M
NEURO-ONCOLOGY. 2023;25(8):1518-1529.

2022

Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial
Hagel C, Sloman V, Mynarek M, Petrasch K, Obrecht D, Kühl J, Deinlein F, Schmid R, von Bueren A, Friedrich C, Juhnke B, Gerber N, Kwiecien R, Girschick H, Höller A, Zapf A, von Hoff K, Rutkowski S
EUR J CANCER. 2022;164:30-38.

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
Juhnke B, Gessi M, Gerber N, Friedrich C, Mynarek M, von Bueren A, Haberler C, Schüller U, Kortmann R, Timmermann B, Bison B, Warmuth-Metz M, Kwiecien R, Pfister S, Spix C, Pietsch T, Kool M, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2022;24(1):127-137.

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
Obrecht D, Mynarek M, Hagel C, Kwiecien R, Spohn M, Bockmayr M, Bison B, Pfister S, Jones D, Sturm D, von Deimling A, Sahm F, von Hoff K, Juhnke B, Benesch M, Gerber N, Friedrich C, von Bueren A, Kortmann R, Schwarz R, Pietsch T, Fleischhack G, Schüller U, Rutkowski S
J NEURO-ONCOL. 2022;157(1):37-48.

2021

Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study
von Hoff K, Haberler C, Schmitt-Hoffner F, Schepke E, de Rojas T, Jacobs S, Zapotocky M, Sumerauer D, Perek-Polnik M, Dufour C, van Vuurden D, Slavc I, Gojo J, Pickles J, Gerber N, Massimino M, Gil-da-Costa M, Garami M, Kumirova E, Sehested A, Scheie D, Cruz O, Moreno L, Cho J, Zeller B, Bovenschen N, Grotzer M, Alderete D, Snuderl M, Zheludkova O, Golanov A, Okonechnikov K, Mynarek M, Juhnke B, Rutkowski S, Schüller U, Pizer B, Zezschwitz B, Kwiecien R, Wechsung M, Konietschke F, Hwang E, Sturm D, Pfister S, von Deimling A, Rushing E, Ryzhova M, Hauser P, Łastowska M, Wesseling P, Giangaspero F, Hawkins C, Figarella-Branger D, Eberhart C, Burger P, Gessi M, Korshunov A, Jacques T, Capper D, Pietsch T, Kool M
NEURO-ONCOLOGY. 2021;23(9):1597-1611.

2020

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort
Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing E, Hasselblatt M, Koch A, Schüller U, von Deimling A, Sahm F, Sill M, Riemenschneider M, Dohmen H, Monoranu C, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Brück W, Filipski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavc I, Gerber N, Grotzer M, Benesch M, Schlegel P, Deinlein F, von Bueren A, Friedrich C, Juhnke B, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann R, Kool M, Rutkowski S
J CLIN ONCOL. 2020;38(18):2028-2040.

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
Ottensmeier H, Schlegel P, Eyrich M, Wolff J, Juhnke B, von Hoff K, Frahsek S, Schmidt R, Faldum A, Fleischhack G, von Bueren A, Friedrich C, Resch A, Warmuth-Metz M, Krauss J, Kortmann R, Bode U, Kühl J, Rutkowski S
PLOS ONE. 2020;15(1):e0227693.

2019

Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series
Benesch M, Mynarek M, Witt H, Warmuth-Metz M, Pietsch T, Bison B, Pfister S, Pajtler K, Kool M, Schüller U, Pietschmann K, Juhnke B, Tippelt S, Fleischhack G, Schmid I, Kramm C, Vorwerk P, Beilken A, Classen C, Hernáiz Driever P, Kropshofer G, Imschweiler T, Lemmer A, Kortmann R, Rutkowski S, von Hoff K
ONCOLOGIST. 2019;24(9):e921-e929.

2017

Refining medulloblastoma subgroups
Juhnke B, Mynarek M, Rutkowski S
LANCET ONCOL. 2017;18(7):847-848.

Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data
Mynarek M, Pizer B, Dufour C, van Vuurden D, Garami M, Massimino M, Fangusaro J, Davidson T, Gil-da-Costa M, Sterba J, Benesch M, Gerber N, Juhnke B, Kwiecien R, Pietsch T, Kool M, Clifford S, Ellison D, Giangaspero F, Wesseling P, Gilles F, Gottardo N, Finlay J, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2017;19(4):576-585.

2016

Evidence of H3 K27M mutations in posterior fossa ependymomas
Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S, Fleischhack G, Scherbaum D, Alfer J, Juhnke B, von Hoff K, Rutkowski S, Warmuth-Metz M, Chavez L, Pfister S, Pietsch T, Jones D, Sturm D
ACTA NEUROPATHOL. 2016;132(4):635-7.

Letzte Aktualisierung aus dem FIS: 18.12.2024 - 03:05 Uhr